Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy

Designation Covers Broad Treatment of Duchenne Muscular Dystrophy (DMD) LOS ANGELES, July 18, 2017 -- (Healthcare Sales & Marketing Network) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duch... Biopharmaceuticals, FDA Capricor Therapeutics, Duchenne muscular dystrophy

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042771

Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news

More News: Biotechnology | Marketing | Muscular Dystrophy | Pediatrics | Reflex Sympathetic Dystrophy